Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Calando Licenses Alnylam RNAi Therapeutic | Contract Pharma

What are you searching for?

Sign in
Breaking News

Calando Licenses Alnylam RNAi Therapeutic

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alnylam Pharmaceuticals has granted Calando Pharmaceuticals an InterfeRx license to discover, develop, and commercialize an RNAi therapeutic towards a cancer target utilizing a synthetic siRNA, together with Calando’s proprietary delivery technology. As part of the agreement, Calando also has an option to acquire an InterfeRx license for a second target gene. Financial terms were not disclosed, but include upfront, annual, and milestone payments, and royalties on sales of any products covered by the licensing agreement.

“Alnylam established the InterfeRx licensing program to provide access to our leading intellectual property estate for disease targets in areas outside the scope of our current research. We are pleased to be granting this license to Calando to enable their efforts with Alnylam intellectual property, which we believe is critical for the development and commercialization of RNAi therapeutics,” said John Maraganore, Ph.D., president and chief executive officer of Alnylam.

“Calando is focused on designing, developing, and commercializing RNAi therapeutics to treat serious medical conditions, such as cancer, by combining effective siRNAs with our patented and proprietary systemic delivery technologies,” said John Petrovich, president and chief executive officer of Calando Pharmaceuticals. “This license from Alnylam is an important step in our efforts to develop and commercialize novel RNAi therapies for serious diseases and conditions requiring systemic delivery.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters